Shares of Crinetics (CRNX) dropped nearly 9% in afternoon trading to $43.52 after the company announced in a regulatory filing that Dana Pizzuti will step down from her position as Chief Medical and Development Officer of the company effective December 31. “Pizzuti will continue her employment with the Company in the role of Strategic Regulatory and Development Advisor for a period of time beginning January 1, 2026, in order to, among other things, provide certain services,” Crinetics said in the filing.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX:
- Crinetics doses first patient in CALM-CAH trial
- CRNX, CYTK, MDGL, SLNO: Top Analyst Outlines Her ‘Top Biotech Ideas for 2026’
- Crinetics announces first patient dosed in Phase 1/2 study of CRN09682
- Crinetics randomizes first patient in CAREFNDR trial
- Buy Rating Justified by Strategic Initiatives and Growth Prospects at Crinetics Pharmaceuticals